U.S., April 24 -- ClinicalTrials.gov registry received information related to the study (NCT07548021) titled 'Safety and PK of MMV371 LAI in Healthy Adults and Adolescents in Rwanda' on April 17.
Brief Summary: This Phase 1b study will assess the safety, tolerability and pharmacokinetics (PK, this measures the levels of study drug in the body) of a single injection of MMV371 in healthy adult and adolescent participants in Rwanda. MMV371 has been designed as a long acting injection (LAI). Protective efficacy (PE) will be assessed as an exploratory endpoint. Protective efficacy measures if participants are protected from becoming ill with malaria whilst the MMV371 is still present in their body. The study will enroll approximately 80 healthy...